{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:48:43Z","timestamp":1792154923999,"version":"4.4.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aimed to evaluate CD47 expression in nonsmall-cell lung cancer (NSCLC) and explore the predictive value of combined CD47 and programmed death-ligand 1 (PD-L1) status for immunotherapy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Specimens from 59 patients with advanced NSCLC who were diagnosed or surgically resected and subsequently received immune checkpoint inhibitors (ICIs) were retrospectively collected for CD47 and PD-L1 detection by immunohistochemistry (IHC) and multiplex fluorescent IHC. A receiver operating characteristic (ROC) curve was constructed to determine the optimal CD47 cutoff value, and patients were categorized into four groups based on the IHC results: low CD47\/negative\u2013low PD-L1, high CD47\/negative\u2013low PD-L1, low CD47\/high PD-L1, and high CD47\/high PD-L1. In addition, the correlation between marker expression and clinical outcomes was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      CD47 positivity was observed in 53 cases, 29 (54.7%) of which showed the coexpression of PD-L1\/CD47. ROC analysis defined the threshold for high CD47 expression as &gt;38.9% stained tumor cells. Multivariate analysis identified CD47 and PD-L1 as independent prognostic factors for immunotherapy efficacy (CD47: PFS\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003, OS\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001; PD-L1: PFS\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.424, OS\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). Subgroup analysis revealed that the low CD47\/high PD-L1 group had the longest progression-free survival (PFS), not reaching the median, whereas the high CD47\/negative\u2013low PD-L1 group had the shortest PFS (median 131 days). Moreover, high CD47 expression was negatively correlated with PFS regardless of PD-L1 level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combined assessment of CD47 and PD-L1 performed excellently in predicting responses to ICIs in advanced NSCLC, and this approach may serve as a potential predictive biomarker for immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1640_25","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:19Z","timestamp":1790766019000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical implications of CD47 and programmed death-ligand 1 expression in predicting the therapeutic response of immune checkpoints in advanced nonsmall-cell lung cancer"],"prefix":"10.4103","volume":"22","author":[{"given":"Shengchao","family":"Miao","sequence":"first","affiliation":[{"name":"Post-doctoral Mobile Research Station, Shandong University of Traditional Chinese Medicine, Jinan, P.R. China"},{"name":"Department of Hematology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Lung Cancer Institute, Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Record Management and Statistics, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Lung Cancer Institute, Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4103\/jcrt.jcrt_2418_24","article-title":"Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer","volume":"21","author":"Chen","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/jcrt.jcrt_1142_25","article-title":"Current status and future prospects of immunotherapy for pancreatic ductal adenocarcinoma","volume":"22","author":"Lou","year":"2026","journal-title":"J Cancer Res Ther"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: Perspective from the international association for the study of lung cancer pathology committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"e13811","DOI":"10.1111\/cts.13811","article-title":"Quantitative systems pharmacology modeling of macrophage-targeted therapy combined with PD-L1 inhibition in advanced NSCLC","volume":"17","author":"Wang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R10-20261016","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: A decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"pkab012","DOI":"10.1093\/jncics\/pkab012","article-title":"Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: Meta-analysis of metastatic NSCLC Trials","volume":"5","author":"Man","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1200\/JCO.22.01748","article-title":"Functional engagement of the PD-1\/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer","volume":"41","author":"S\u00e1nchez-Magraner","year":"2023","journal-title":"J Clin Oncol"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: A perspective from the international association for the study of lung cancer pathology committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"189294","DOI":"10.1016\/j.bbcan.2025.189294","article-title":"CD47 as a potent target in cancer immunotherapy: A review","author":"Ahvati","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer 2025"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"102291","DOI":"10.1016\/j.tranon.2025.102291","article-title":"CD47 is a tumor cell-derived exosomal signature and regulates tumor immune microenvironment and immunotherapy responses","volume":"53","author":"Luan","year":"2025","journal-title":"Transl Oncol"},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"119150","DOI":"10.1016\/j.lfs.2021.119150","article-title":"The role of CD47-SIRP\u03b1 immune checkpoint in tumor immune evasion and innate immunotherapy","volume":"273","author":"Li","year":"2021","journal-title":"Life Sci"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.2024027222","article-title":"Targeting CD47: Many misses; hopeful for a hit","volume":"145","author":"Wilde","year":"2025","journal-title":"Blood"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/08820139.2024.2415409","article-title":"The physiological and therapeutic role of CD47 in macrophage function and cancer","volume":"54","author":"Bess","year":"2025","journal-title":"Immunol Investig"},{"key":"R23-20261016","doi-asserted-by":"crossref","first-page":"150066","DOI":"10.1016\/j.bbrc.2024.150066","article-title":"CD47-mediated immune evasion in early-stage lung cancer progression","volume":"720","author":"Chuang","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1038\/s41467-023-42972-2","article-title":"Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Nat Commun"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.3390\/cancers15215229","article-title":"CD47: The next frontier in immune checkpoint blockade for non-small cell lung cancer","volume":"15","author":"Lau","year":"2023","journal-title":"Cancers"},{"key":"R26-20261016","first-page":"9435030","article-title":"CD47-SIRP\u03b1 axis as a biomarker and therapeutic target in cancer: Current perspectives and future challenges in nonsmall cell lung cancer","author":"Catal\u00e1n","year":"2020","journal-title":"J Immunol Res 2020"},{"key":"R27-20261016","doi-asserted-by":"crossref","first-page":"eabd7455","DOI":"10.1126\/sciadv.abd7455","article-title":"Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells","volume":"7","author":"Guo","year":"2021","journal-title":"Sci Adv"},{"key":"R28-20261016","first-page":"5612","article-title":"CD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway","volume":"11","author":"Yao","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"R29-20261016","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jid.2023.02.017","article-title":"Blockade of the immune checkpoint CD47 by TTI-621 potentiates the response to anti-PD-L1 in cutaneous T-cell lymphoma","volume":"143","author":"Han","year":"2023","journal-title":"J Invest Dermatol"},{"key":"R30-20261016","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4103\/jcrt.jcrt_2094_24","article-title":"Effectiveness and safety of percutaneous microwave ablation and radiofrequency ablation in the treatment of pulmonary metastasis: A systematic review and meta-analysis","volume":"21","author":"Xu","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R31-20261016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/jcrt.jcrt_2414_25","article-title":"Efficacy and safety of Xihuang pill\/capsule as adjuvant therapy for lung cancer: A systematic review and meta-analysis","volume":"22","author":"Guan","year":"2026","journal-title":"J Cancer Res Ther"},{"key":"R32-20261016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/jcrt.jcrt_2333_24","article-title":"Association between tissue origin classification and the clinical features and molecular phenotypes of nonsmall cell lung cancer","volume":"22","author":"Zhou","year":"2026","journal-title":"J Cancer Res Ther"},{"key":"R33-20261016","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"R34-20261016","doi-asserted-by":"crossref","first-page":"29719","DOI":"10.1038\/srep29719","article-title":"CD47 promotes tumor invasion and metastasis in non-small cell lung cancer","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci Rep"},{"key":"R35-20261016","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J Clin Invest"},{"key":"R36-20261016","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/cam4.2882","article-title":"Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer","volume":"9","author":"Arrieta","year":"2020","journal-title":"Cancer Med"},{"key":"R37-20261016","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s00432-019-03023-w","article-title":"PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: A predictor of poor prognosis and potential targets of future combined immunotherapy","volume":"145","author":"Yang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R38-20261016","doi-asserted-by":"crossref","first-page":"e000823","DOI":"10.1136\/esmoopen-2020-000823","article-title":"Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer","volume":"5","author":"Xu","year":"2020","journal-title":"ESMO Open"},{"key":"R39-20261016","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/diagnostics12081859","article-title":"CD47 expression in non-melanoma skin cancers and its clinicopathological implications","volume":"12","author":"Bang","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R40-20261016","doi-asserted-by":"crossref","first-page":"e0314228","DOI":"10.1371\/journal.pone.0314228","article-title":"CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration","volume":"19","author":"Zhang","year":"2024","journal-title":"PLoS One"},{"key":"R41-20261016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7150\/thno.79367","article-title":"Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"R42-20261016","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R43-20261016","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-20261016","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells","volume":"236","author":"Wang","year":"2021","journal-title":"J Cell Physiol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1640_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:34Z","timestamp":1792152094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1640_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1640_25","relation":{},"ISSN":["1998-4138","0973-1482"],"issn-type":[{"value":"1998-4138","type":"print"},{"value":"0973-1482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}